Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study
Tomoaki Ueda, Kentaro Fukushima, Sunggi Chi, Hiroshi Haeno, Goichi Yoshimoto, Hironori Arai, Daisuke Ikeda, Motoshi Ichikawa · 2026
Read Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study by Tomoaki Ueda, Kentaro Fukushima, Sunggi Chi, Hiroshi Haeno, Goichi Yoshimoto, Hironori Arai, Daisuke Ikeda, Motoshi Ichikawa (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0357898.txt.
Description
Ueda and seven co-authors published a 2026 PLOS ONE study on treating acute myeloid leukemia, a fast-growing blood cancer. They looked at which gene traits and clinical traits predict response to two drugs used together, azacitidine and venetoclax. The data came from a Japanese study program coded HM-SCREEN-Japan 02. Knowing who is likely to respond helps doctors pick the right therapy early for each patient.
Catalog record
| CREATOR | Tomoaki Ueda, Kentaro Fukushima, Sunggi Chi, Hiroshi Haeno, Goichi Yoshimoto, Hironori Arai, Daisuke Ikeda, Motoshi Ichikawa |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46034 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |